BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19967752)

  • 1. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    O'Quigley J
    Stat Med; 2009 Dec; 28(30):3745-50; discussion 3759-60. PubMed ID: 19967752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Rosenberger WF; Manukyan Z
    Stat Med; 2009 Dec; 28(30):3751-3; discussion 3759-60. PubMed ID: 19967756
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Atkinson AC
    Stat Med; 2009 Dec; 28(30):3739-41; discussion 3759-60. PubMed ID: 19967753
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary on 'Designs of dose-escalation trials with quantitative responses'.
    Haines LM
    Stat Med; 2009 Dec; 28(30):3742-4; discussion 3759-60. PubMed ID: 19967751
    [No Abstract]   [Full Text] [Related]  

  • 5. Designs for dose-escalation trials with quantitative responses.
    Bailey RA
    Stat Med; 2009 Dec; 28(30):3721-38. PubMed ID: 19579226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Senn S
    Stat Med; 2009 Dec; 28(30):3754-8; discussion 3759-60. PubMed ID: 19967754
    [No Abstract]   [Full Text] [Related]  

  • 7. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004.
    Buoen C; Bjerrum OJ; Thomsen MS
    J Clin Pharmacol; 2005 Oct; 45(10):1123-36. PubMed ID: 16172177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escalation, group and A + B designs for dose-finding trials.
    Ivanova A
    Stat Med; 2006 Nov; 25(21):3668-78. PubMed ID: 16381057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
    Wang M; Day R
    J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal designs for estimating the most successful dose.
    Zohar S; O'Quigley J
    Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive designs for Phase I dose-finding studies.
    Zhou Y
    Fundam Clin Pharmacol; 2010 Apr; 24(2):129-38. PubMed ID: 19703268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designs for phase I clinical trials with multiple courses of subjects at different doses.
    Fan SK; Wang YG
    Biometrics; 2007 Sep; 63(3):856-64. PubMed ID: 17403103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved up-and-down designs for phase I trials.
    Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD
    Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-finding in phase I clinical trials based on toxicity probability intervals.
    Ji Y; Li Y; Nebiyou Bekele B
    Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-escalation designs in oncology: ADEPT and the CRM.
    Shu J; O'Quigley J
    Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision-theoretic designs for dose-finding clinical trials with multiple outcomes.
    Fan SK; Wang YG
    Stat Med; 2006 May; 25(10):1699-714. PubMed ID: 16217860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trials: from traditional to newer approaches part II.
    Macaluso M; Krams M; Preskorn SH
    J Psychiatr Pract; 2011 Jul; 17(4):277-84. PubMed ID: 21775829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of sequential dose-finding designs.
    O'Quigley J
    Biometrics; 2005 Sep; 61(3):749-56. PubMed ID: 16135026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.